HomeAdvocacy and research – November 2023

Advocacy and research – November 2023

November 3, 2023

Learn about how you can share your input on eating out with food allergy, and read about our latest advocacy with food manufacturers. Plus, learn about how to participate in a new research study for children with peanut allergy. 

Advocacy: Have your say and participate in our survey – ENDS TONIGHT 

Share your experiences eating out with food allergy. In support of our efforts to work with industry and policymakers on food allergen management in foodservice outlets, we want your input. 

Take our short 15-minute survey to share your experiences on eating out and ordering food from a restaurant or foodservice establishment. To be eligible, you or your child must have a formal food allergy diagnosis. 

The survey ends tonight! Don’t miss out in sharing your thoughts, take the survey now. 

Advocacy: Annual Food Manufacturer’s Stakeholder Council Meeting 

This month, we hosted our annual food industry meeting with our Food Manufacturer’s Stakeholder Council in Toronto, ON. The Council is comprised of members of the Canadian food industry who are committed to working with us to help advance allergen management practices within food manufacturing.

Bringing together this core group of manufacturers provided us with the opportunity to share current challenges related to food allergen labelling and discuss potential paths forward to better help you make informed food choices. 

We were honoured to have international food allergy experts at our meeting, including Dr. Paul Turner, Reader in Paediatric Allergy & Immunology at Imperial College London UK, Dr. Samuel Godefroy, Full Professor of Food Risk Analysis and Regulatory Policies, Department of Food Science, Faculty of Agriculture and Food Sciences, Université Laval, as well representatives from Health Canada and the Canadian Food Inspection Agency. 

We look forward to collaborating with the Council and being your voice at the table.  

Research study — Call for participants: Children with peanut allergy 

A research study is underway across North America. They are seeking children aged 4-7 years who have been diagnosed with peanut allergy and are currently following a strict peanut-free diet.  

The study is testing an investigational drug patch to learn how well it works and how safe it is in children with peanut allergy. The purpose of the patch is to potentially desensitize a person with peanut allergy by repeated exposures to very small amounts of peanut via the skin. 

Following is an announcement from the research team. You can also visit VitesseAllergyStudy.com for more details and view their FAQ sheet. Please note, study sites will continue to be added, so check back often.

Please share with others whose children have peanut allergy.   

From the research team: 

Now Enrolling: The VITESSE Phase 3 Study for Peanut Allergy

The VITESSE phase 3 clinical research study is looking for children 4 to 7 years of age who have been diagnosed with peanut allergy and are currently following a strict peanut-free diet. Study doctors are testing an investigational drug patch (also called study drug patch) to learn how well it works and how safe it is in children with peanut allergy.  

What should I know about the VITESSE study?

  • To be eligible for this study, participants must be*:
    • 4 to 7 years of age
    • Diagnosed with peanut allergy 
    • Currently following a strict peanut-free diet

*Other inclusion/exclusion criteria will apply.

  • This study will consist of at least 12 study visits and 5 phone calls over a period of approximately 58 weeks (about 1 year) 
  • Participants will be randomly assigned (by chance) to receive the study drug patch or placebo patch (looks like the study drug but contains no active drug). Participants will have about a 67% (2 in 3) chance of receiving the study drug patch and about a 33% (1 in 3) chance of receiving the placebo patch
  • The health and safety of participants will be monitored throughout the study
  • Participant data and information will be kept confidential according to applicable laws for clinical research studies
  • Study participants will receive all study-related procedures and the study drug patch or placebo patch at no cost

To learn more about the VITESSE phase 3 study and eligibility criteria, please visit VitesseAllergyStudy.com or ClinicalTrials.gov (identifier: NCT05741476).

Study sponsored by DBV Technologies.

Tags: , , ,